Parkinson's disease is a progressive neurodegenerative disorder affecting movement and non-motor functions, driven by degeneration of dopamine-producing neurons in the brain.
Bayer outlined its 2030 growth strategy at Pharma Media Day 2026, driven by AI partnerships, precision medicine, and a strengthened pipeline. The company aims for mid-single-digit growth from 2027 and 30% margins by 2030.
ACADIA Pharmaceuticals' stock jumped after the European Medicines Agency recommended approval of its Rett syndrome drug Daybue. The company also reported strong quarterly results and progress on its Alzheimer's disease psychosis treatment.
MRI-guided brain stimulation achieved 80% response rates for treatment-resistant depression versus 60% with conventional targeting, per a JAMA Psychiatry study. Separately, Barcelona researchers developed an MRI tool to accurately identify rare neurodegenerative tauopathies PSP and CBD, while experts in Paris discussed AI's growing role in predictive psychiatry.
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
A $9 million grant from ASAP and The Michael J. Fox Foundation funds an Indiana University-led study on immune cell exhaustion in Parkinson's disease, aiming to develop personalized immunotherapies. The multi-institutional team will map immune system changes to uncover biomarkers and explain disease heterogeneity. Advances in proteomics are also enabling molecular subtyping and precision medicine across neurological disorders.
Japan's health ministry panel is reviewing two regenerative cell therapies for Parkinson's disease and heart failure, testing the country's push to build a domestic cell-based treatment industry. Japan's cell culture market is projected to reach USD 2.34 billion by 2031, driven by government support and favorable regulatory pathways. Australian firm Cartherics secured a Japanese patent for its iPSC-based immune cell therapies.
Rare diseases affect an estimated 25-30 million Americans, yet 95% lack FDA-approved treatments. Families affected by conditions like SLC6A1-related disorders and Anti-IgLON5 Autoimmune Encephalitis voice concerns about drug pricing policies that could slow medical innovation. Advocates urge lawmakers to protect research investment while sharing stories of diagnostic challenges and treatment breakthroughs.
A new cerebrospinal fluid biomarker for DOPA decarboxylase (DDC) shows strong diagnostic potential for Lewy body disorders including Parkinson's disease and dementia with Lewy bodies. Validated across multiple cohorts, CSF DDC levels were significantly elevated in these conditions with high diagnostic accuracy. The biomarker correlated with alpha-synuclein pathology but plasma levels showed no diagnostic value.
Quantitative and functional MRI techniques are gaining traction as biomarkers in neurodegenerative diseases. A consensus statement provides MRI endpoint recommendations for clinical trials in hereditary ataxias like SCA and Friedreich ataxia. Separately, research shows resting-state fMRI can distinguish subtypes of multiple system atrophy and may improve early diagnosis.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597421 |
Fecal Microbiota Transplantation in Parkinson's Disease. |
NOT_YET_RECRUITING | NA |
| NCT07592767 |
RESvEraTrol in Parkinson's Disease (RESET) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07585565 |
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07570212 |
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders |
RECRUITING | NA |
| NCT07569133 |
Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Depressive Symptoms in Patients With Parkinson's Disease |
ENROLLING_BY_INVITATION | NA |
| NCT07536022 |
At-home taVNS for Neurorehabilitation in Parkinson's Disease |
NOT_YET_RECRUITING | NA |
| NCT07514858 |
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations |
NOT_YET_RECRUITING | PHASE2 |
| NCT07442747 |
Neural Mechanisms of Aerobic Exercise Benefits in PD With DBS |
NOT_YET_RECRUITING | NA |
| NCT07441915 |
Auditory Sleep Stimulation or Sham in People With Parkinson Disease Mild Cognitive Impairment During Cognitive Training |
RECRUITING | NA |
| NCT07403539 |
Speech Learning and Speech Production in Parkinson's Disease |
RECRUITING | NA |
